Drugs / AMLISIMOD
AMLISIMOD
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04535947 | Aug 2020 → Feb 2021 | dry eye syndrome | Silk Technologies, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03889886 | Apr → Oct 2019 | dry eye syndrome | Silk Technologies, Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMLISIMOD | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594346 ↗ |
| Known as | SDP-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04535947 ↗ |
| Known as | Silk-derived protein-4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594346 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4594346 ↗ |
| Route | Topical | “administered via topical ocular instillation” NCT03889886 ↗ |